Date: 2013-10-03
Type of information: Collaboration agreement
Compound: IMX313
Company: Imaxio (France) Vitamfero (France)
Therapeutic area: Infectious diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On October 4, 2013, Imaxio and VitamFero have announced the conclusion of an R&D partnership agreement. According to the terms of the agreement, the two firms will evaluate the combination of IMX313, Imaxio\'s pro-immunogenic technology, and VitamFero\'s live attenuated parasites, for vaccines development. Imaxio, a biopharmaceutical company based in Lyons, develops a pipeline of vaccines based on its proprietary antigen re-engineering technology, IMX313, that enables significant increase of immunogenicity and efficacy of vaccines with which it is used. VitamFero, a biotech firm of the Genopole cluster, develops veterinary vaccines against several infectious diseases, essentially parasitic, for which there is a big unmet prophylactic need. To that end, VitamFero uses live attenuated parasitic strains, of which it holds the rights. Within the framework of this collaboration, Imaxio\'s IMX313 technology will be combined with VitamFero\'s live attenuated strains in order to identify immunogenic synergies between the two vaccine approaches, and thus to potentiate the efficacy of future vaccine candidates.
Financial terms:
Latest news:
